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Abstract
The transgenic and knock out (KO) animals involving Fgf23 have been highly informative in 
defining novel aspects of mineral metabolism, but are limited by shortened life span, inability of 
spatial/temporal FGF23 control, and infertility of the global KO. To more finely test the role of 
systemic and genetic influences in FGF23 production, a mouse was developed that carried a floxed 
(‘f’)-Fgf23 allele (exon 2 floxed) which demonstrated in vivo recombination when bred to global-
Cre transgenic mice (eIIa-cre). Mice homozygous for the recombined allele (‘Δ’) had undetectable 
serum intact FGF23, elevated serum phosphate (p<0.05), and increased kidney Cyp27b1 mRNA 
(p<0.05) similar to global Fgf23-KO mice. To isolate cellular FGF23 responses during phosphate 
challenge Fgf23Δ/f mice were mated with early osteoblast type Iα1 collagen 2.3kb promoter-cre 
mice (Col2.3-cre) and the late osteoblast/early osteocyte Dentin matrix protein-1-cre (Dmp1-cre). 
Fgf23Δ/f/Col2.3-cre+ and Fgf23Δ/f/Dmp1-cre+ exhibited reduced baseline serum intact FGF23 
versus controls. After challenge with high phosphate diet Cre− mice had 2.1–2.5 fold increased 
serum FGF23 (p<0.01), but Col2.3-cre+ mice had no significant increase, and Dmp1-cre+ mice 
had only a 37% increase (p<0.01) despite prevailing hyperphosphatemia in both models. The 
Fgf23Δ/f/Col2.3-cre was bred onto the Hyp (murine XLH model) genetic background to test the 
contribution of osteoblasts and osteocytes to elevated FGF23 and Hyp disease phenotypes. 
Whereas Hyp mice maintained inappropriately elevated FGF23 considering their marked 
hypophosphatemia, Hyp/Fgf23Δ/f/Col2.3-cre+ mice had serum FGF23 <4% of Hyp (p<0.01), and 
this targeted restriction normalized serum phosphorus and ricketic bone disease. In summary, 
deleting FGF23 within early osteoblasts and osteocytes demonstrated that both cell types 
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contribute to baseline circulating FGF23 concentrations, and that targeting osteoblasts/osteocytes 
for FGF23 production can modify systemic responses to changes in serum phosphate 
concentrations and rescue the Hyp genetic syndrome.
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Introduction
Phosphate is central to basic cellular functions and is essential for proper mineralization of 
bone, therefore blood phosphate concentrations are maintained within a fairly narrow range. 
Serum phosphate levels are controlled by a balance of endocrine effects on intestinal uptake 
from the diet, coupled with renal handling and storage in bone (1). Fibroblast growth 
factor-23 (FGF23) is a key hormone involved in maintaining phosphate balance, primarily 
through control of renal phosphate reabsorption (2). In kidney, FGF23 interacts with its co-
receptor αKlotho (αKL) and an FGF receptor (FGFR) to activate the MAPK pathway (3, 4). 
These interactions decrease expression of the renal proximal tubule sodium phosphate 
cotransporters NPT2a and NPT2c, responsible for renal phosphate reabsorption (5, 6). In 
parallel, serum 1,25(OH)2 vitamin D (1,25D) is reduced through FGF23-dependent down 
regulation of the anabolic 1α-hydroxylase (CYP27b1), and increased catabolic enzyme 24-
hydroxylase (CYP24a1) expression (5). FGF23 is primarily produced in bone (7), and 
FGF23 mRNA and circulating concentrations are influenced by multiple factors including 
systemic changes in phosphate (8), 1,25D (9, 10), PTH (11), iron handling (12), as well as 
local factors including FGF/FGFR1 signaling (13, 14). Although thought to be primarily 
produced in osteocytes, which cells in bone are the source(s) of FGF23, as well as the 
mechanisms directing the ability of bone cells to produce FGF23 downstream of the 
aforementioned factors remain unclear.
Several heritable and acquired metabolic bone diseases are caused by disturbances in 
FGF23. In this regard, an increase in circulating bioactive FGF23 is associated with 
autosomal dominant hypophosphatemic rickets (ADHR) (15), autosomal recessive 
hypophosphatemic rickets type 1–3 (ARHR1: mutations in DMP1; ARHR2: mutations in 
ENPP1; and ARHR3: mutations in FAM20C (Raine syndrome) (16–19)), X-linked 
hypophosphatemic rickets (XLH) (20), as well as tumor induced osteomalacia (TIO) (5, 20). 
Although these syndromes have heterogeneous genetic causes, they share a common 
phenotype of elevated FGF23, leading to hypophosphatemia secondary to renal phosphate 
wasting with inappropriately low or normal serum 1,25D. The reciprocal disorder to ADHR, 
familial hyperphosphatemic tumoral calcinosis (hFTC), is caused by loss of function 
mutations in FGF23 (21, 22), the O-glycosylating enzyme GALNT3 (23), and αKL (24). 
The GALNT3 and FGF23 mutations result in destabilized FGF23 protein and thus low 
circulating intact hormone (25, 26). End organ resistance to serum FGF23 is the likely cause 
of the severe hyperphosphatemia due to αKL inactivating mutations observed in humans 
(24) and in the global αKl knock-out (KO) mice (4). The mouse models of transgenic 
FGF23 excess (6, 27) and global Fgf23-KO (28, 29) have been useful in determining some 
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of the molecular mechanisms underlying genetic diseases resulting from alterations in 
FGF23 bioactivity. These models have proven to phenocopy the majority of the key 
phenotypes in aforementioned diseases of FGF23 excess and reduction. However, the 
cellular mechanisms and localization of FGF23 production during changes in serum 
phosphate and in genetic disorders involving FGF23 are unknown. Additionally, the 
currently available animal models are characterized by severe endocrine and skeletal 
manifestations and are therefore limited by shortened life span, inability of spatial and 
temporal FGF23 control, and infertility of the global Fgf23-KO (6, 27–30).
To more finely examine FGF23 expression and function in vivo, a mouse harboring a 
conditional Fgf23 allele (flox-Fgf23) was developed. With osteoblast/osteocyte lineage-
specific recombination, conditional-null Fgf23 mice had suppressed circulating intact 
FGF23 that was resistant to normal responses to phosphate challenge. Further, when bred 
onto the genetic background of the XLH mouse model Hyp, characterized by an osteoblast 
differentiation defect and aberrant FGF23 production despite prevailing hypophosphatemia, 
the recombined Fgf23 allele rescued hallmark endocrine and skeletal disease phenotypes. 
These findings support that osteocytes and osteoblasts control baseline circulating FGF23, 
and that targeting osteoblast/osteocyte FGF23 disrupts normal systemic responses to 
changes in phosphate handling.
Materials and Methods
Animal studies
Animal studies were approved by and performed according to the Institutional Animal Care 
and Use Committee (IACUC) for Indiana University, and comply with the NIH guidelines 
for the use of animals in research. Flox-Fgf23 mice were derived as described immediately 
below and Hyp mice were purchased as live stock (JAX; Bar Harbor, ME). In Hyp studies, 
littermates were injected with calcein (10 mg/kg) at 7 days, then alizarin red (20 mg/kg) at 2 
days, prior to necropsy and tissue harvest according to standard protocols.
Generation of a conditional Fgf23 allele
Exon 2 of the mouse Fgf23 gene was targeted for Cre-mediated recombination, since 
deletion of this exon is predicted to result in a truncation of FGF23 protein (Supplemental 
Figure 1). To this end, a 9.4 kb target region of mouse Fgf23 identified from BAC clone 
RP23:142M1 was subcloned into the pSP72 backbone plasmid. A single LoxP site was 
inserted downstream of exon 2. The 1.7 kb pGK-gb2 LoxP/FRT-flanking Neomycin cassette 
(NeoR) was inserted upstream of exon 2, which contained new BamHI and NcoI restriction 
sites. Restriction enzyme digests and sequencing confirmed the final targeting vector 
(depicted in Supplemental Figure 2). The targeting vector was separated from the vector 
backbone with NotI and injected into BA1 ES cells. Positive ES cell clones were identified 
with G418 selection, and homologous recombination events within the Fgf23 locus 
(Supplemental Figure 2) were confirmed with PCR and Southern blotting (Supplemental 
Figure 2). ES cell DNA were digested with NcoI and probed with a 462 bp 3′-external probe 
for long arm recombination. DNA digested with BamHI and probed with a 515 bp 5′- 
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internal probe confirmed short arm homologous recombination (Supplemental Figure 2) as 
designed by InGenious, Inc. (Ronkonkoma, NY).
Conditional deletion of Fgf23 in mice
Chimeric mice were mated to the FLP-Cre transgenic mice (C57BL/6 FLP: stock#005703; 
JAX, Bar Harbor, ME) to simultaneously assess germline transmission and delete the FRT-
neomycin resistance (NeoR) cassette, confirmed through PCR genotyping. The F1-
generation heterozygous flox-Fgf23 (Fgf23f/+) mice were either intercrossed to generate 
homozygous flox (Fgf23f/f) mice, or bred to generate Fgf23f/+/Cre+/− and Fgf23Δ/+ 
(Δ=recombined Fgf23 allele) mice using the eIIa-cre (JAX), the 2.3kb promoter rat type Iα1 
collagen-cre (Col2.3-cre) (31), and the 8kb-Dentin matrix protein 1 (Dmp1)-cre (32) mouse 
lines. Fgf23Δ/f littermates positive or negative for the appropriate transgenic Cre were used 
for subsequent analysis. For analysis of phenotypes arising from matings between Hyp and 
Fgf23-flox mice, controls labeled as ‘Hyp’ were genotyped as carrying the known Hyp Phex 
3′ deletion (33) with at least one wild type (‘+’) Fgf23 allele, or carry at least one floxed-
Fgf23 allele (Fgf23f) and are Cre−: Hyp/Fgf23Δ/f/Col2.3-cre−, Hyp/Fgf23f/+/Col2.3-cre+/−, 
and Hyp/Fgf23Δ/+/Col2.3-cre+. For comparisons, phenotypically normal littermate mice 
were wild type for Phex and genotyped as Fgf23Δ/+/Col2.3-cre+, Fgf23Δ/f/Col2.3-cre−, or 
Fgf23f/f/Col2.3-cre−.
Rodent diets
Mice were weaned at three weeks of age and maintained until euthanasia at 8 weeks on a 
standard rodent diet (0.7% phosphate and 1.0% calcium, Harlan-Teklad, Inc.; Madison, WI). 
To induce FGF23 production littermates were placed on a high phosphate (‘HighP’) diet 
containing 1.65% phosphate and 1.0% calcium (Diet #TD 88345; Harlan-Teklad), from 6 
weeks of age for 2 weeks. Diets and water were provided ad libitum throughout the 
experimental time frames.
Serum biochemistries
Blood samples were collected from mice at the time of euthanasia by cardiac puncture, or 
for interim analyses by facial vein bleed according to approved protocols. Routine serum 
biochemistries were determined in the Laboratory of the Clinical and Translational Sciences 
Institute (CTSI) of the Indiana University School of Medicine using an automated COBAS 
MIRA Plus Chemistry Analyzer (Roche Diagnostics; Indianapolis, IN), or using the 
Inorganic Phosphorous Reagent kit (Pointe Scientific, Inc.; Brussels, Belgium). Serum 
‘intact’ FGF23, and ‘total or C-terminal’ FGF23 concentrations were assessed using 
commercial ELISAs (Kainos Laboratories Int’l; Tokyo, Japan (intact); or Immutopics, Int’l; 
San Clemente, CA (intact and C-terminal)). Serum intact PTH was measured using 
commercial ELISA (Immutopics Int’l.).
Micro-computed tomography (μCT)
Femurs were removed post-necropsy and fixed in 4% PFA. Bones were scanned using μCT 
(Skyscan 1172), at 6 micron resolution, to assess trabecular and cortical bone morphometry. 
A defined region of interest in the distal femur (~0.5 mm from the growth plate and 
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encompassing 1 mm of slices in the proximal direction) was used to determine trabecular 
bone volume/total volume (BV/TV). A single cortical bone slice (2 mm proximal to the 
above region of interest) was analyzed for cortical geometry. The terminology and units used 
are those recommended by the American Society for Bone and Mineral Research Guidelines 
for assessment of bone microstructure in rodents using μCT (34).
Histomophometric analyses
Following μCT analysis, bones were embedded in methyl methacrylate using standard 
protocols. Mid-sagittal (4 μm) sections of cancellous bone from the distal femur and 
transverse (~100 μm) sections of the mid-diaphysis were cut using a microtome (Reichert-
Jung 2050 Supercut; Leica Microsystems, Buffalo Grove, IL) and wire-saw (Histosaw; 
Delaware Diamond Knives), respectively. The cancellous sections were stained with von 
Kossa tetrachrome according to established protocols. Diaphysis sections were ground to 
roughly 40 μm thickness. Periosteal and endocortical dynamic bone parameters were 
obtained using a semi- automatic analysis system (Bioquant OSTEO; Bioquant Image 
Analysis Co.) attached to a Nikon microscope. The terminology and units used are those 
recommended by the Histomorphometry Nomenclature Committee of the American Society 
for Bone and Mineral Research (35).
RNA preparation and quantitative RT-PCR (qPCR)
Kidneys were harvested and homogenized in 1 mL of Trizol reagent (Invitrogen/Life 
Technologies, Inc.; Grand Island, NY) according to the manufacturer’s protocol using a 
TissueTearor rotor-stator (Biospec Products, Inc.; Bartlesville, OK), then further purified 
using the RNeasy Kit (Qiagen, Inc.; Germantown, MD). RNA samples were tested with 
intron-spanning primers specific for Fgf23, and vitamin D 1α-hydroxylase (Cyp27b1) 
mRNAs; mouse β-actin was used as an internal control. The qPCR primers and probes were 
purchased as pre-optimized reagents (Applied Biosystems/Life Technologies, Inc.). The 
TaqMan One-Step RT-PCR kit was used to perform qPCR. PCR conditions for all 
experiments were: 30 min 48°C, 10 min 95°C, followed by 40 cycles of 15 sec 95°C and 1 
min 60°C. The data was collected and analyzed by a 7500 Real Time PCR or StepOne Plus 
systems (Applied Biosystems/Life Technologies, Inc.). The expression levels of mRNAs 
were calculated relative to appropriate littermate genotype controls, and the 2−ΔΔCT method 
described by Livak was used to analyze the data (36).
DNA sequencing
Sequencing of genomic DNA following ella-cre-mediated recombination of the flox-Fgf23 
alleles was performed using standard PCR (KOD DNA Polymerase; EMD-Millipore, Inc.) 
to generate gene fragments followed by Exosap (Affymetrix, Inc.; Santa Clara, CA) 
preparation of templates. Dideoxysequencing was carried out on the genomic fragments by a 
commercial vendor (SeqWright Genomic Services; Houston, TX) using the forward or 
reverse PCR primers.
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Statistical analysis
Statistical analysis of the in vivo and in vitro data was performed by one-way ANOVA 
followed by a Tukey post-hoc test and Student’s t-test, respectively. Significance for all tests 
was set at p<0.05. Data are presented as means ± standard error of the mean (SEM).
Results
Development of a murine model harboring an FGF23 conditional-null allele
To develop an in vivo model carrying conditional-null alleles for Fgf23, mouse exon 2 was 
targeted for Cre-mediated recombination (LoxP sites in introns 1 and 2; diagrammed in 
Figure 1A (upper panel)), as deletion of this exon is predicted to cause frame shift mutations 
after residue 70 and a stop codon after residue 89 in the predicted FGF23 protein 
(Supplemental Figure 1). The LoxP-Fgf23 construct (see Methods) was delivered to ES 
cells, and standard protocols were used to derive mice chimeric for the floxed Fgf23 allele. 
As determined by PCR and sequencing of founder line DNA, germline transmission of the 
flox-Fgf23 allele (‘flox’ or ‘f’ allele; Fgf23f/+ mice; Figure 1A (lower panel)) was 
confirmed. Following initial Fgf23f/+ intercrosses, it was determined that the mice carrying 
homozygous, non-recombined LoxP-Fgf23 alleles (Fgf23f/f) were normal for serum 
phosphate, calcium, alkaline phosphatase, and intact and C-terminal FGF23 concentrations 
from 5–19 weeks of age when compared to Fgf23f/+ and WT (Fgf23+/+) littermates (see 
complete listing of biochemistries: Supplemental Table 1).
To test Cre-mediated recombination of the flox-Fgf23 allele, Fgf23f/+ mice were mated with 
widely-expressed eIIa-Cre transgenic mice by standard breeding regimen. Using PCR 
primers that spanned the floxed exon 2 region (Figure 1A), a 743 bp PCR product was 
amplified from genomic DNA of these mice (the ‘Δ’ allele; Figure 1B). When sequenced, 
this product showed the expected deletion of exon 2 with the junction of introns 1 and 3 with 
a single intervening LoxP site (Supplemental Figure 3). These results demonstrated that the 
LoxP sites within introns 1 and 2 flanking Fgf23 exon 2 were correctly targeted and did not 
alter baseline FGF23 expression and phosphate metabolism.
Testing the functional LoxP-Fgf23 allele in vivo
To determine whether the Δ allele was null for FGF23 expression, the Fgf23Δ/+ mice were 
either intercrossed, or Fgf23f/f mice were bred with Fgf23Δ/+/ella-cre+ mice. Offspring with 
fully recombined Fgf23 (Fgf23Δ/f/ella-cre+; i.e. genotyped as harboring no remnant intact 
floxed-Fgf23 alleles following exposure to Cre, approximately 40% of offspring) were much 
smaller than control littermates (Figure 1C). Biochemical analyses revealed that these 
Fgf23Δ/f/ella-cre+ mice had undetectable serum intact FGF23 (p<0.01; Figure 1D), which 
paralleled the lack of measureable serum intact FGF23 in Fgf23Δ/Δ mice (not shown). 
Similar to the reported Fgf23-KO mice, the Fgf23Δ/f/ella-cre+ mice were hyperphosphatemic 
compared to controls (p<0.05; Figure 1D) (28, 29), and had modestly, but not significantly 
reduced serum calcium. These mice also had elevated kidney vitamin D 1α-hydroxylase 
mRNA (Cyp27a1, p<0.05; Figure 1D), consistent with the loss of FGF23-mediated 
suppression of this gene. Intercrossed Fgf23Δ/Δ mice had undetectable serum intact FGF23 
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and undetectable femur Fgf23 mRNA (Supplemental Figure 4). Thus, targeted deletion of 
Fgf23 exon 2 produced a conditional allele null for FGF23 expression.
Bone-specific FGF23 deletion and phosphate challenge
To test the contribution and localization of phosphate-sensitive FGF23 production, Fgf23Δ/f 
mice (heterozygous Δ mice were used to potentially reduce the background of FGF23-
expressing alleles) were bred to the Type Ia1 collagen 2.3kb promoter-cre transgenic line 
(Col2.3-cre, known to target early osteoblasts through to osteocytes. At 8 weeks of age, 
Fgf23Δ/f/Col2.3-cre+ mice maintained on control diet had serum intact FGF23 ~50% of 
same genotype Fgf23Δ/f/Col2.3-cre− littermates (p<0.01; Figure 2A) which corresponded 
with a 75% reduction in femur Fgf23 mRNA (Figure 2A, inset). Additional phenotypes 
emerged when mice were placed on a two-week high phosphate (‘HighP’) diet at six weeks 
of age to induce FGF23 production (diet previously reported (8)). After receiving the HighP 
diet, the Fgf23Δ/f/Col2.3-cre− mice increased serum intact FGF23 2.1 fold (p<0.01 versus 
control diet; Figure 2A). In contrast, the Fgf23Δ/f/Col2.3-cre+ mice only slightly elevated 
intact FGF23, with serum concentrations significantly reduced compared to Fgf23Δ/f/Col2.3-
cre− mice receiving control or HighP diets (p<0.01; Figure 2A), consistent with an inability 
to produce FGF23 in response to changes in serum phosphate.
Next, to target FGF23 in osteocytes, the late osteoblast/osteocyte 8kb-promoter Dentin 
matrix protein-1-cre (Dmp1-cre) transgenic line was bred onto the flox-Fgf23 background. 
Similar to the crosses with Col2.3-cre, Fgf23Δ/f/Dmp1-cre+ mice had a 40% reduction of 
basal intact FGF23 on control diet versus Fgf23Δ/f/Dmp1-cre− controls (p<0.01; Figure 2B) 
and consistent with osteocytes maintaining basal FGF23 expression. Femur Fgf23 mRNA 
was reduced, but did not reach statistical significance (Figure 2B, inset). With the provision 
of the HighP diet, Fgf23Δ/f/Dmp1-cre− mice showed a significant increase in intact FGF23 
(p<0.01; Figure 2B) whereas the Fgf23Δ/f/Dmp1-cre+ mice had a positive, but markedly 
blunted response (37% increased versus Fgf23Δ/f/Dmp1-cre− mice, p<0.001; Figure 2B). 
Although differences in Cre efficiencies cannot be ruled out at this time, the increase in 
serum FGF23 following Dmp1-cre exposure and HighP diet was greater than the induction 
in Fgf23Δ/f/Col2.3-cre+ mice (p<0.01; Figure 2B).
Coincident with reduced FGF23 during phosphate challenge, the Fgf23Δ/f/Col2.3-cre+ mice 
had elevated serum phosphate concentrations versus Fgf23Δ/f/Col2.3-cre− mice (p<0.01; 
Figure 2C), and versus same genotype, control diet littermates (p<0.01; Figure 2C). Serum 
phosphate was not different between Fgf23Δ/f/Dmp1-cre− and Fgf23Δ/f/Dmp1-cre+ mice 
during control diet consumption, but after HighP diet, there was a significant elevation in 
both genotypes (p<0.05; Figure 2C), with a further elevation in the Fgf23Δ/f/Dmp1-cre+ 
mice (p<0.05; Figure 2C). Serum calcium levels were not different between genotype or 
dietary challenge (Figure 2D), and alkaline phosphatase was slightly reduced in Fgf23Δ/f/
Col2.3-cre+ mice receiving HighP diet (p<0.05; Figure 2E). Serum PTH levels also 
responded to the HighP diet, as both the Fgf23Δ/f/Col2.3-cre− and Fgf23Δ/f/Dmp1-cre− mice 
showed a significant increase compared to those receiving control diet (p<0.05; Figure 2F). 
In contrast, PTH was not significantly increased in the Fgf23Δ/f/Col2.3-cre+ or Fgf23Δ/f/
Dmp1-cre+ mice receiving the HighP diet (Figure 2F). No calcifications were observed in 
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the osteoblast/osteocyte targeted conditional mice. The Fgf23Δ/f/Col2.3-cre+/− and Fgf23Δ/f/
Dmp1-cre+/− mice were also fed a high phosphate and low calcium diet reported to increase 
FGF23 (37); this diet produced similar results as the HighP diet for serum intact FGF23 
(Supplemental Figure 5). Thus, when FGF23 was targeted in both osteoblasts and osteocytes 
using the Col2.3-cre, there was only a slight increase but when deleted from a more mature 
cell population with the Dmp1-cre, FGF23 showed a modest increase. These findings 
support that both osteoblasts and osteocytes contribute to basal and phosphate-sensitive 
serum FGF23 concentrations.
Rescue of the Hyp phenotype with bone-specific Fgf23 targeting
The metabolic bone disorder XLH is due to loss of function mutations in the Phosphate 
regulating gene with homology to endopeptidases (PHEX)(1, 38). The murine XLH model 
Hyp has a large 3′ Phex deletion and reflects the majority of the XLH patient disease 
phenotypes including elevated FGF23, small size, hypophosphatemia with inappropriately 
normal 1,25D, and rickets/osteomalacia (39, 40). It was previously demonstrated that when 
Hyp and global Fgf23-KO mice were crossed, the offspring produced were not grossly and 
biochemically different from the Fgf23-KO mice (28, 29), as the Hyp/Fgf23-KO mice were 
small, hyperphosphatemic, had skeletal and ectopic calcifications, and undetectable serum 
FGF23 (28, 29). Although the role of PHEX in phosphate handling remains unclear, its loss 
of function mutations were previously shown to result in excess FGF23 produced during an 
osteoblast/osteocyte differentiation defect, therefore Fgf23 was targeted on the Hyp 
background using the osteoblast Col2.3-cre. In contrast to Hyp/Fgf23Δ/+/Col2.3-cre+/− 
(‘Hyp’) mice, Hyp/Fgf23Δ/f/Col2.3-cre+ mice resembled Fgf23Δ/+/Col2.3-cre+ 
(phenotypically normal) mice and were normalized for body size (Figure 3A), as well as 
femur (Figure 3B) and tail length (Figure 3B). At baseline (4 weeks of age) circulating intact 
FGF23 in Hyp/Fgf23Δ/f/Col2.3-cre+ mice was ~40% of Fgf23Δ/+/Col2.3-cre+ (p<0.01) and 
<4% of Hyp concentrations (p<0.01; Figure 3C), and did not vary over the time course (up 
to 8 weeks of age) as assessed by interim bleeds (Figure 3C). The Hyp mouse is known to 
manifest reduced serum phosphate and elevated PTH, which was confirmed (Figure 3D). 
Consistent with reversal of the Hyp disease phenotypes, serum phosphate and PTH in Hyp/
Fgf23Δ/f/Col2.3-cre+ mice was normal versus Hyp mice (p<0.01 and p<0.05, respectively; 
Figure 3D) and not different from Fgf23Δ/+/Col2.3-cre+ mice (Figure 3D). Thus, in contrast 
to complete ablation of Fgf23, reduction of serum FGF23 to below WT baseline levels can 
rescue Hyp disease phenotypes without the severe manifestations of hyperphosphatemia.
The Hyp skeletal phenotype is characterized by osteomalacia, abnormal growth plate, as 
well as widened distal metaphyses due to the prevailing hypophosphatemia and inhibited 
mineralization. As observed by μCT, compared to femurs from Fgf23Δ/+/Col2.3-cre+ mice, 
femurs from Hyp/Fgf23Δ/f/Col2.3-cre+ mice displayed almost normal shape, lacking the 
widened distal metaphysis and growth plate typically observed in Hyp mice (1, 39), while 
also exhibiting higher trabecular bone volume (Figure 4A). Indeed, the metaphyses of Hyp/
Fgf23Δ/f/Col2.3-cre+ femurs lacked marrow space or trabeculae definition due to the 
abundant bone, and had markedly increased metaphyseal trabecular BV/TV, compared to 
Hyp and Fgf23Δ/+/Col2.3-cre+ (Table 1). This osteopetrotic phenotype was not found by 
μCT in Fgf23Δ/f/Col2.3-cre+ mice (not shown). In cortical bone, Hyp/Fgf23Δ/f/Col2.3-cre+ 
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cortical thickness and bone area/tissue area (BA/TA) were normalized versus Hyp femurs to 
levels similar to Fgf23Δ/+/Col2.3-cre+ (Table 1). Cortical porosity was also high in Hyp 
femurs (Table 1). Von Kossa staining showed a dramatic correction of the osteomalacia in 
Hyp/Fgf23Δ/f/Col2.3-cre+, in concert with increased mineralized bone (Figure 4C), 
consistent with the μCT scans. Qualitative evaluation of the growth plate revealed almost 
complete rescue with prototypical alignment of proliferative chondrocytes and hypertrophic/
apoptotic chondrocytes in the Hyp/Fgf23Δ/f/Col2.3-cre+. There was also clear ossification of 
cartilage in the lower portions of the plate. Dynamic histomorphometry analyses showed 
distinct separation of labels in Hyp/Fgf23Δ/f/Col2.3-cre+ femurs, similar to Fgf23Δ/+/Col2.3-
cre+ mice, whereas Hyp displayed very poor label uptake and virtually no separation, in 
accord with its well-characterized mineralization impairment (Figure 4D). Mineral 
apposition rate, mineralizing surface, and bone formation rate/bone surface were similar 
between Hyp/Fgf23Δ/f/Col2.3-cre+ and Fgf23Δ/+/Col2.3-cre+ for both the periosteal and 
endocortical surfaces (Table 1). Therefore, targeted reduction of FGF23 in Hyp restores 
bone length but cannot overcome the intrinsic Hyp osteoblastic defects to fully normalize 
general architecture.
In summary, when Fgf23 is targeted in the early osteoblast and in osteocytes, the 
recombined Fgf23 allele produces an animal with serum concentrations significantly 
reduced in the basal state, supporting that osteoblasts and osteocytes contribute to normal 
circulating FGF23 concentrations. Dietary phosphate challenge demonstrated the ability of 
these cells to respond to increased serum phosphorus by inducing FGF23. Ultimately, 
inability of FGF23 to fully respond to this challenge in the conditional deletion models 
resulted in hyperphosphatemia. Finally, recombination of the Fgf23 allele in early 
osteoblasts demonstrated that over-riding the Hyp defect of inappropriate and elevated 
FGF23 production during hypophosphatemia by restricting serum FGF23 to below WT 
levels rescued the majority of disease manifestations.
Discussion
The use of genetic mouse models that delete or over express critical components of the 
FGF23 bone-kidney signaling axis have markedly enhanced the understanding of phosphate 
metabolism. Global Fgf23 knockout mice are phenotypically similar to wild type (WT) 
littermates at birth (28–30). These mice then become severely hyperphosphatemic with 
elevated serum calcium and 1,25D over the next several weeks (28–30). FGF23 interacts 
with an FGF receptor (FGFR) and αKL in the kidney to elicit a renal phosphaturic response 
(3, 4). Consistent with FGF23-αKL interactions, homozygous deletion of murine αKl results 
in an animal exhibiting a phenotype virtually identical to the Fgf23-KO mice, with 
hyperphosphatemia, elevated 1,25D, and reduced PTH (4). The primary endocrine difference 
between Fgf23-null and αKl-null is that the latter have markedly elevated circulating FGF23 
(4), likely as a compensatory response to end-organ resistance of the kidneys to FGF23 
signaling, and a positive feedback loop resulting from the prevailing elevated 1,25D and 
hyperphosphatemia. Indeed, placing αKl-null mice on a low phosphate diet (41) or mating 
the Fgf23-KO mouse to the Vdr-KO mouse (42) normalizes the overwhelming majority of 
the endocrine manifestations, establishing defective phosphate metabolism as the primary 
source of the disease phenotypes. Using the global eIIa-cre, we determined that the floxed-
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Fgf23 allele could undergo homologous recombination. This Cre line is known to have 
mosaicism (43, 44), however a substantial portion of the flox-Fgf23/eIIa-cre offspring fully 
recapitulated the phenotype of the global Fgf23-KO mice. In comparison to the global 
Fgf23-null mice, while receiving a normal diet the Fgf23 conditional-null mice crossed with 
the Col2.3- and Dmp1-cre transgenic lines had normal serum phosphate concentrations, 
PTH, calcium, and alkaline phosphatase. Importantly, intact serum FGF23 concentrations 
were approximately 50% of the respective Cre- controls. Upon challenge with high 
phosphate diet, the Cre+ mice could not maintain normal phosphate metabolism, and similar 
to the global Fgf23-KO had elevated serum phosphate with normocalcemia. PTH was 
similarly elevated in the flox-Fgf23/Col2.3-cre− and flox-Fgf23/Dmp1-cre− mice receiving 
HighP diet, however this effect was blunted in the flox-Fgf23/Col2.3-cre+ and flox-Fgf23/
Dmp1-cre+ mice. Whether this response was to due to direct or indirect effects of the 
inability to fully increase FGF23 in response to high phosphate diet remains to be 
determined. The localization of the cell populations that increase FGF23 in response to 
elevated serum phosphate in these models (and patients) are unclear however, as to date no 
‘stand-alone’ phosphate sensing receptor analogous to the calcium-sensing receptor (CASR) 
has been identified. Herein, it was demonstrated that targeted deletion of FGF23 from both 
osteoblasts and osteocytes restricted the ability of mice to normalize serum phosphate 
following challenge with high phosphate diet. Indeed, when comparing floxed-Fgf23 mice 
that were bred onto the Col2.3-cre or the Dmp1-cre backgrounds, both groups had reduced 
basal intact FGF23 concentrations. When challenged with high phosphate diet, the Col2.3-
cre+ mice could not significantly elevate FGF23 above their reduced basal levels, whereas 
the Dmp1-cre+ mice had the ability to partially compensate, and raised FGF23 
approximately 35–40% of Dmp1-cre− mice. FGF23 production in osteocytes is critical to 
disease models such as the Dmp1-KO mouse (modeling ARHR type 1) (16), the deletion of 
FGF23 from both early osteoblasts and late osteoblast/osteocytes compromises the ability to 
respond to phosphate challenge, thus osteoblasts and osteocytes play a significant role in 
phosphate-mediated FGF23 production. Additionally, the mechanisms responsible for the 
biological ‘set point’ for circulating FGF23 and serum phosphate are unknown. It has been 
shown that normal individuals’ serum FGF23 levels vary quite widely but that serum 
phosphate is maintained within a fairly narrow range (20, 45, 46). We found that selective 
FGF23 deletion in osteoblasts or osteocytes similarly reduced baseline concentrations yet 
did not elicit a global knockout phenotype, therefore multiple cell types may be responsible 
for maintenance of normal circulating intact FGF23.
Mouse models involving pathways that post-translationally modify FGF23 have also been 
important for relating patient phenotypes to molecular disease mechanisms. Animals null for 
the O-glycosylating enzyme GalNAc-T3 (Galnt3) cannot glycosylate FGF23 on threonine 
(T) 178 within the FGF23 proprotein convertase R176HT178R179/SAE motif, and thus 
produce FGF23 that is rapidly cleaved by the intracellular protease furin (25). These mice 
produce intact FGF23 at concentrations approximately 50% of WT, similar to our results for 
the Fgf23Δ/f/Col2.3-cre and Fgf23Δ/f/Dmp1-cre mice at baseline. Provision of a high 
phosphate diet to Galnt3-KO mice results in tumoral calcinosis phenotype (47), reflective of 
some patients with loss of function mutations in GALNT3 (23, 48, 49). We found that with 
phosphate challenge both Fgf23/Col2.3-cre and Fgf23/Dmp1-cre conditional-nulls retained 
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the capacity to produce some intact FGF23, at approximately one-half of the basal level of 
WT mice. With exposure to bone specific Cre expression, these mice were also 
hyperphosphatemic upon high phosphate dietary challenge. This expression profile is 
reflective of patients with hfTC GALNT3 and FGF23 missense mutations (21, 22, 50), 
where the ability to produce FGF23 at minimal levels and carry out low-level renal 
phosphate metabolism likely prevents early death, as reported in complete Fgf23-null mice 
(28, 29) or a severe hfTC phenotype as reported in a family with an FGF23 deletion and 
missense mutation (51). Serum FGF23 was detectable after targeting recombination to 
osteoblasts and osteocytes, therefore it is possible that FGF23 is also produced in other cell 
types within bone such as chondrocytes (52), or extra-skeletal tissues such as skin and brain 
(53), as well as heart (54). Additionally, it cannot be ruled out at this time that some 
inefficiency of the respective Cre transgenic lines accounts in part for the detectable serum 
FGF23. The contributions of these other potential sites to circulating FGF23 at baseline and 
during phosphate diet challenge is currently unknown. Therefore, future studies targeting 
cells outside of osteoblasts and osteocytes will be important for understanding FGF23 
bioactivity under normal circumstances and during disease modeling.
The knockout models involving FGF23 and its co-receptor αKL have been used in breeding 
strategies to genetically determine the mechanisms underlying diseases of FGF23 over 
production. When the global Fgf23-KO was crossed with the mouse model of XLH, the Hyp 
mouse, the Fgf23-KO phenotype dominated the Hyp phenotype causing severe 
hyperphosphatemia. (28, 29). The Hyp mouse has a defect in osteoblast differentiation, 
producing cortical bone cells with elevated Type 1 collagen, matrix protein disturbances 
(40), as well as increased alkaline phosphatase and FGF23 (7, 55, 56). Additionally, this 
model has an intrinsic defect whereby FGF23 is approximately 10-fold elevated in the face 
of significant hypophosphatemia (57), typically a potent FGF23 suppressor via negative 
feedback. We found that when Fgf23 was targeted in the Hyp/Fgf23Δ/f/Col2.3-cre cross, the 
mice had relatively normal body size, but markedly elevated bone volume as well as normal 
femur length and shape, as opposed to the Hyp manifestations of stunted growth and 
widened metaphyses due to the severe hypophosphatemia (39). Our findings demonstrated 
that deleting Fgf23 from osteoblasts/osteocytes in Hyp ablates the manifestations of the 
inappropriately elevated FGF23, as well as supported the concept that providing even a 
minor amount of FGF23-dependent phosphate metabolism allows the skeleton to more 
appropriately develop. However, the Hyp/XLH intrinsic cellular defect in the context of 
slight hyperphosphatemia due to loss of FGF23 resulted in over-mineralization of trabecular 
bone in Hyp/Fgf23Δ/f/Col2.3-cre+ mice. In the reported global Hyp/Fgf23-KO mice, bone 
length and BMD were not restored to WT values, but this cross did show an area of intense 
mineralization proximal to the growth plate (29), similar to the Hyp/Fgf23Δ/f/Col2.3-cre+ 
mice. In the Hyp/αKl-KO cross, bone length also remained shortened and thus similar to 
αKl-KO mice and far shorter than in WT. However, Hyp/αKl-KO mice had significantly 
increased trabecular bone density with levels above those of WT controls (58). The Hyp/
Fgf23Δ/f/Col2.3-cre cross resulted in notable rescue of bone length and normalization of 
bone shape versus Hyp mice. It is unclear why rescue of specific portions of the skeletal 
phenotype, such as shape, occurs when FGF23 bioactivity is absent during global deletion of 
Fgf23 (28), but bone length is not. Although not directly tested herein, with similarly 
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reduced baseline serum FGF23 concentrations between the flox-Fgf23/Col2.3-cre and flox-
Fgf23/Dmp1-cre mice, taken together with early expression of Dmp1 in Hyp osteoblasts/
osteocytes (59), it is anticipated that a Hyp/flox-Fgf23/Dmp1-cre cross could produce a 
similar rescue. A circulating form of αKL (‘cKL’) may interact with osteoblasts (60), but 
whether blood αKL affects bone development in the Fgf23-null environment is currently 
unknown.
Novel therapies that involve inhibiting FGF23 activity with neutralizing antibodies are 
currently in clinical trials for XLH (61, 62), and were previously shown to correct the major 
manifestations of hypophosphatemic rickets in the Hyp mouse (63). The Hyp/Fgf23Δ/f/
Col2.3-Cre cross resulted in significant reductions in circulating FGF23 compared to Hyp 
and WT mice, and rescued the hypophosphatemia and Hyp skeletal disease phenotypes with 
almost complete restoration of normal bone length and shape. These findings support that 
the inhibition of bioactive FGF23 production to at least one-half of control serum 
concentrations (or <4% of Hyp) can restore almost normal phosphate metabolism associated 
with uncontrollable FGF23 excess. Converse to loss of function mutations in FGF23, αKL, 
and GALNT3, FGF23 transgenic mice whether under control of the Type 1 collagen 
promoter (Col1a1) (6) or β-actin (27), have severe hypophosphatemia with little to no 
change in serum calcium, low 1,25D levels and reduced bone mineral density (BMD) (6, 
27). A murine model of the ADHR syndrome carrying an R176Q-Fgf23 point mutation can 
be induced to express elevated FGF23 and an ADHR phenotype during iron deficiency 
anemia (12, 64). Additionally, although genetically distinct, global or bone-specific 
conditional knockout of Dmp1 (human DMP1 mutations cause autosomal recessive 
hypophosphatemic rickets (ARHR) Type 1) (16), and the kinase Family with sequence 
similarity 20, member C (FAM20C; mutations cause ARHR Type 3 or ‘Raine syndrome’) 
(65) result in animals that over express FGF23 and manifest a hypophosphatemic rickets 
phenotype similar to Hyp mice. Consistent with its proposed role as a key mediator of renal 
phosphate handling, mice with a common denominator of high circulating FGF23 reproduce 
the majority of the biochemical and skeletal defects of patients with ADHR, ARHR, XLH 
and TIO. Thus, our results support the idea that control of FGF23 bioactivity through a 
targeted, conditional approach could also be useful for dissecting heterogeneous disease 
mechanisms as well as for testing specific therapeutic approaches in diverse models of 
FGF23 over production through FGF23 reduction in specific cell populations.
In summary, an animal with a conditional Fgf23 allele was developed, and demonstrated that 
osteoblasts and osteocytes contribute to the maintenance of normal circulating FGF23 levels. 
Finally, restricting osteoblasts/osteocytes from inappropriately over-producing FGF23 
during prevailing hypophosphatemia can rescue severe Hyp phenotypes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors would like to acknowledge NIH grants R21-AR059278, R01-DK063934 and R01-DK95784 (KEW); 
F32-AR065389 (ELC); T32-HL007910 and an American Heart Association Postdoctoral Fellowship 
Clinkenbeard et al. Page 12
J Bone Miner Res. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
16POST-27260108 (JMH); R01-AR062002 (MRA); R01-AR059357 and VA-BX002104 (TB); the Indiana 
Genomics Initiative (INGEN), supported in part by the Lilly Endowment, Inc.; The David Weaver Professorship 
and a Showalter Scholar award through the Ralph W. and Grace M. Showalter Research Trust (KEW). The authors 
also thank Jeff Lavigne from Immutopics, Int’l. for initial provision of rodent intact FGF23 ELISAs, Dr. Alex 
Robling for assistance with the radiographs, and Anthony Acton for assistance with biochemical analyses.
Bibliography
1. Tenenhouse, HS.; Econs, MJ. The Metabolic and Molecular Bases of Inherited Disease;. Valle, D., 
editor. New York: The McGraw-Hill Companies; 2001. p. 1-9.
2. White KE, Larsson TE, Econs MJ. The roles of specific genes implicated as circulating factors 
involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix 
extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev. 2006; 27(3):221–
41. [PubMed: 16467171] 
3. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu 
MC, Moe OW, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 
2006; 281(10):6120–3. [PubMed: 16436388] 
4. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, 
Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 
2006; 444(7120):770–4. [PubMed: 17086194] 
5. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, 
Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced 
osteomalacia. Proc Natl Acad Sci USA. 2001; 98(11):6500–5. [PubMed: 11344269] 
6. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson 
KB. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) 
collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. 
Endocrinology. 2004; 145(7):3087–94. [PubMed: 14988389] 
7. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth 
factor 23 expression but not degradation by PHEX. J Biol Chem. 2003; 278(39):37419–26. 
[PubMed: 12874285] 
8. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum 
phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D 
metabolism in mice. Endocrinology. 2005; 146(12):5358–64. [PubMed: 16123154] 
9. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD. Fibroblast growth factor 23 is a 
counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006; 17(5):1305–15. 
[PubMed: 16597685] 
10. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, 
Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate 
homeostasis. J Bone Miner Res. 2004; 19(3):429–35. [PubMed: 15040831] 
11. Rhee Y, Bivi N, Farrow E, Lezcano V, Plotkin LI, White KE, Bellido T. Parathyroid hormone 
receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and 
in vivo. Bone. 2011; 49(4):636–43. [PubMed: 21726676] 
12. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, 
Jideonwo V, Magers MJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic 
rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad 
Sci U S A. 2011; 108(46):E1146–55. [PubMed: 22006328] 
13. Xiao L, Esliger A, Hurley MM. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone 
marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro. J Bone Miner Res. 
2013; 28(1):35–45. [PubMed: 22836867] 
14. Xiao Z, Huang J, Cao L, Liang Y, Han X, Quarles LD. Osteocyte-specific deletion of Fgfr1 
suppresses FGF23. PLoS One. 2014; 9(8):e104154. [PubMed: 25089825] 
15. ADHR-Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations 
in FGF23. Nature genetics. 2000; 26(3):345–8. [PubMed: 11062477] 
Clinkenbeard et al. Page 13
J Bone Miner Res. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
16. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, et al. Loss of 
DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. 
Nature genetics. 2006; 38(11):1310–5. [PubMed: 17033621] 
17. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, 
Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, et al. DMP1 mutations in autosomal 
recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate 
homeostasis. Nature genetics. 2006; 38(11):1248–50. [PubMed: 17033625] 
18. Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM. Loss-of-function ENPP1 
mutations cause both generalized arterial calcification of infancy and autosomal-recessive 
hypophosphatemic rickets. Am J Hum Genet. 2010; 86(2):267–72. [PubMed: 20137773] 
19. Ababneh FK, AlSwaid A, Youssef T, Al Azzawi M, Crosby A, AlBalwi MA. Hereditary deletion 
of the entire FAM20C gene in a patient with Raine syndrome. Am J Med Genet A. 2013; 
161A(12):3155–60. [PubMed: 24039075] 
20. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson 
G, Koshiyama H, Ljunggren O, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and 
X-linked hypophosphatemia. N Engl J Med. 2003; 348(17):1656–63. [PubMed: 12711740] 
21. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE. A novel recessive 
mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol 
Metab. 2005; 90(4):2424–7. [PubMed: 15687325] 
22. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes 
familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2005; 14(3):385–90. 
[PubMed: 15590700] 
23. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, 
Petronius D, Friedman V, et al. Mutations in GALNT3, encoding a protein involved in O-linked 
glycosylation, cause familial tumoral calcinosis. Nature genetics. 2004; 36(6):579–81. [PubMed: 
15133511] 
24. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, 
White KE, Econs MJ. A homozygous missense mutation in human KLOTHO causes severe 
tumoral calcinosis. J Clin Invest. 2007; 117(9):2684–91. [PubMed: 17710231] 
25. Ichikawa S, Sorenson AH, Austin AM, Mackenzie DS, Fritz TA, Moh A, Hui SL, Econs MJ. 
Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) 
concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology. 2009; 
150(6):2543–50. [PubMed: 19213845] 
26. Bergwitz C, Banerjee S, Abu-Zahra H, Kaji H, Miyauchi A, Sugimoto T, Juppner H. Defective O-
glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast 
growth factor 23 secretion and tumoral calcinosis. J Clin Endocrinol Metab. 2009; 94(11):4267–
74. [PubMed: 19837926] 
27. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, 
Fukumoto S, Yamashita T. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with 
reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 
2004; 314(2):409–14. [PubMed: 14733920] 
28. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B. 
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired 
skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix biology : journal of 
the International Society for Matrix Biology. 2004; 23(7):421–32. [PubMed: 15579309] 
29. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. 
Am J Physiol Endocrinol Metab. 2006; 291(1):E38–49. [PubMed: 16449303] 
30. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka 
K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 
in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113(4):561–8. [PubMed: 14966565] 
31. Liu F, Woitge HW, Braut A, Kronenberg MS, Lichtler AC, Mina M, Kream BE. Expression and 
activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. The 
International journal of developmental biology. 2004; 48(7):645–53. [PubMed: 15470637] 
Clinkenbeard et al. Page 14
J Bone Miner Res. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
32. Yang W, Lu Y, Kalajzic I, Guo D, Harris MA, Gluhak-Heinrich J, Kotha S, Bonewald LF, Feng JQ, 
Rowe DW, et al. Dentin matrix protein 1 gene cis-regulation: use in osteocytes to characterize 
local responses to mechanical loading in vitro and in vivo. J Biol Chem. 2005; 280(21):20680–90. 
[PubMed: 15728181] 
33. Lorenz-Depiereux B, Guido VE, Johnson KR, Zheng QY, Gagnon LH, Bauschatz JD, Davisson 
MT, Washburn LL, Donahue LR, Strom TM, et al. New intragenic deletions in the Phex gene 
clarify X-linked hypophosphatemia-related abnormalities in mice. Mamm Genome. 2004; 15(3):
151–61. [PubMed: 15029877] 
34. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for 
assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner 
Res. 2010; 25(7):1468–86. [PubMed: 20533309] 
35. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. 
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the 
ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2(6):595–610. 
[PubMed: 3455637] 
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative 
PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001; 25(4):402–8. [PubMed: 11846609] 
37. Sabbagh Y, Graciolli FG, O’Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song 
W, Bracken C, et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the 
progression of renal osteodystrophy. J Bone Miner Res. 2012; 27(8):1757–72. [PubMed: 
22492547] 
38. HYP-Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-
linked hypophosphatemic rickets. The HYP Consortium. Nature genetics. 1995; 11(2):130–6. 
[PubMed: 7550339] 
39. Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, Tenenhouse HS. 
Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked 
hypophosphatemic mice. J Clin Invest. 1997; 99(6):1200–9. [PubMed: 9077527] 
40. Miao D, Bai X, Panda D, McKee M, Karaplis A, Goltzman D. Osteomalacia in hyp mice is 
associated with abnormal phex expression and with altered bone matrix protein expression and 
deposition. Endocrinology. 2001; 142(2):926–39. [PubMed: 11159866] 
41. Segawa H, Yamanaka S, Ohno Y, Onitsuka A, Shiozawa K, Aranami F, Furutani J, Tomoe Y, Ito 
M, Kuwahata M, et al. Correlation between hyperphosphatemia and type II Na-Pi cotransporter 
activity in klotho mice. Am J Physiol Renal Physiol. 2007; 292(2):F769–79. [PubMed: 16985213] 
42. Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG. Ablation of vitamin D signaling rescues 
bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix biology : journal of the 
International Society for Matrix Biology. 2007; 26(2):75–84. [PubMed: 17123805] 
43. Lakso M, Pichel JG, Gorman JR, Sauer B, Okamoto Y, Lee E, Alt FW, Westphal H. Efficient in 
vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci U S A. 
1996; 93(12):5860–5. [PubMed: 8650183] 
44. Holzenberger M, Lenzner C, Leneuve P, Zaoui R, Hamard G, Vaulont S, Bouc YL. Cre-mediated 
germline mosaicism: a method allowing rapid generation of several alleles of a target gene. 
Nucleic acids research. 2000; 28(21):E92. [PubMed: 11058142] 
45. Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal 
dominant hypophosphatemic rickets. J Bone Miner Res. 2007; 22(4):520–6. [PubMed: 17227222] 
46. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, 
Nakahara K, Yamashita T, et al. Increased circulatory level of biologically active full-length 
FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 
87(11):4957–60. [PubMed: 12414858] 
47. Ichikawa S, Gray AK, Padgett LR, Reilly AM, Unsicker TR. High dietary phosphate intake 
induces development of ectopic calcifications in a murine model of familial tumoral calcinosis. J 
Bone Miner Res. 2014; 29(9):2017–23. [PubMed: 24692172] 
48. Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D, Richard G, Sprecher E. 
Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-
Clinkenbeard et al. Page 15
J Bone Miner Res. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J Mol Med. 
2005; 83(1):33–8. [PubMed: 15599692] 
49. Garringer HJ, Fisher C, Larsson TE, Davis SI, Koller DL, Cullen MJ, Draman MS, Conlon N, Jain 
A, Fedarko NS, et al. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-
acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix 
extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab. 2006; 
91(10):4037–42. [PubMed: 16868048] 
50. Garringer HJ, Malekpour M, Esteghamat F, Mortazavi SM, Davis SI, Farrow EG, Yu X, Arking 
DE, Dietz HC, White KE. Molecular genetic and biochemical analyses of FGF23 mutations in 
familial tumoral calcinosis. Am J Physiol Endocrinol Metab. 2008; 295(4):E929–37. [PubMed: 
18682534] 
51. Shah A, Miller CJ, Nast CC, Adams MD, Truitt B, Tayek JA, Tong L, Mehtani P, Monteon F, 
Sedor JR, et al. Severe vascular calcification and tumoral calcinosis in a family with 
hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing. 
Nephrol Dial Transplant. 2014; 29(12):2235–43. [PubMed: 25378588] 
52. Raimann A, Ertl DA, Helmreich M, Sagmeister S, Egerbacher M, Haeusler G. Fibroblast growth 
factor 23 and Klotho are present in the growth plate. Connective tissue research. 2013; 54(2):108–
17. [PubMed: 23206185] 
53. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, 
preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res 
Commun. 2000; 277(2):494–8. [PubMed: 11032749] 
54. Leifheit-Nestler M, Grosse Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler WH, Klintschar 
M, Becker JU, Erbersdobler A, Aufricht C, et al. Induction of cardiac FGF23/FGFR4 expression is 
associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial 
Transplant. 2015
55. Liu S, Tang W, Zhou J, Vierthaler L, Quarles LD. Distinct roles for intrinsic osteocyte 
abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. 
Am J Physiol Endocrinol Metab. 2007; 293(6):E1636–44. [PubMed: 17848631] 
56. Farrow EG, Summers LJ, Schiavi SC, McCormick JA, Ellison DH, White KE. Altered renal 
FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation. J Endocrinol. 
2010; 207(1):67–75. [PubMed: 20675303] 
57. Ichikawa S, Austin AM, Gray AK, Econs MJ. A Phex mutation in a murine model of X-linked 
hypophosphatemia alters phosphate responsiveness of bone cells. J Bone Miner Res. 2012; 27(2):
453–60. [PubMed: 22006791] 
58. Brownstein CA, Zhang J, Stillman A, Ellis B, Troiano N, Adams DJ, Gundberg CM, Lifton RP, 
Carpenter TO. Increased bone volume and correction of HYP mouse hypophosphatemia in the 
Klotho/HYP mouse. Endocrinology. 2010; 151(2):492–501. [PubMed: 19952276] 
59. Miyagawa K, Yamazaki M, Kawai M, Nishino J, Koshimizu T, Ohata Y, Tachikawa K, Mikuni-
Takagaki Y, Kogo M, Ozono K, et al. Dysregulated gene expression in the primary osteoblasts and 
osteocytes isolated from hypophosphatemic Hyp mice. PLoS One. 2014; 9(4):e93840. [PubMed: 
24710520] 
60. Smith RC, O’Bryan LM, Farrow EG, Summers LJ, Clinkenbeard EL, Roberts JL, Cass TA, Saha J, 
Broderick C, Ma YL, et al. Circulating alphaKlotho influences phosphate handling by controlling 
FGF23 production. J Clin Invest. 2012; 122(12):4710–5. [PubMed: 23187128] 
61. Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, 
Zhang X, Humphrey J, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked 
hypophosphatemia. J Clin Invest. 2014; 124(4):1587–97. [PubMed: 24569459] 
62. Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, 
Glorieux FH, Portale AA, et al. Prolonged Correction of Serum Phosphorus in Adults With X-
Linked Hypophosphatemia Using Monthly Doses of KRN23. J Clin Endocrinol Metab. 2015; 
100(7):2565–73. [PubMed: 25919461] 
63. Aono Y, Shimada T, Yamazaki Y, Hino R, Takeuchi Y, Fujita T, Fukumoto S, Nagano N, Wada M, 
Yamashita T. The neutralization of FGF-23 ameliorates hypophosphatemia and rickets in Hyp 
mice. J Bone Miner Metab. 2003; 18(S16)
Clinkenbeard et al. Page 16
J Bone Miner Res. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
64. Clinkenbeard EL, Farrow EG, Summers LJ, Cass TA, Roberts JL, Bayt CA, Lahm T, Albrecht M, 
Allen MR, Peacock M, et al. Neonatal Iron Deficiency Causes Abnormal Phosphate Metabolism 
by Elevating FGF23 in Normal and ADHR Mice. J Bone Miner Res. 2014; 29(2):361–9. 
[PubMed: 23873717] 
65. Wang X, Wang S, Li C, Gao T, Liu Y, Rangiani A, Sun Y, Hao J, George A, Lu Y, et al. 
Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. 
PLoS Genet. 2012; 8(5):e1002708. [PubMed: 22615579] 
Clinkenbeard et al. Page 17
J Bone Miner Res. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Phenotypes following flox-Fgf23 recombination
(A) (upper panel): Schematic of Flox-Fgf23 allele showing Fgf23 exons 1–3, positions of 
genotyping and sequencing forward (F1) and reverse (R1, R2) PCR primers before (top) and 
after (bottom) Cre-mediated recombination; location of LoxP sites surrounding Fgf23 exon 
2 (triangles) and remaining Flp recognition target (FRT) site (open arrowhead) shown; 
(lower panel): Gel electrophoresis of PCR amplification encompassing the proximal LoxP 
site (primers F1/R1) demonstrated PCR products discernable for wild type (‘+/+’), 
heterozygous (‘f/+’), or homozygous (‘f/f’) flox-Fgf23 alleles. (B) PCR amplification of 
genomic DNA (primers F1/R2) resulted in products of the expected sizes from Fgf23f/f 
alleles (1978 bp) and the recombined Fgf23Δ/Δ alleles (743 bp) (DNA markers are on left, in 
bp: lambda virus HindIII fragments and 100 bp DNA ladder); (C) Radiographs showed that 
compared to Fgf23f/f (f/f eIIa-cre−) and Fgf23Δ/+ (Δ/+ eIIa-cre−) mice, Fgf23Δ/f/ella-cre+ 
(Δ/f ella-cre+) mice were smaller, and had: (D) undetectable serum FGF23, significantly 
elevated serum phosphate, similar serum calcium, and elevated kidney vitamin D 1α-OHase 
(*p<0.05 and ╪p<0.01 vs (f/f) and (Δ/+) respectively, n=3–5 mice per group).
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Figure 2. Bone cell-specific targeting of Fgf23 and responses to phosphate challenge
(A) Serum intact FGF23 was tested in Fgf23Δ/f/Col2.3-cre− (Δ/f Cre−) and Fgf23Δ/f/Col2.3-
cre+ (Δ/f Cre+) mice receiving a control or a high phosphate (‘HighP’) diet. Baseline serum 
intact FGF23 was reduced in the Fgf23Δ/f/Col2.3-cre+ mice at 8 weeks, and with 2 week 
HighP diet challenge was suppressed compared to Fgf23Δ/f/Col2.3-cre− mice (**p<0.01 vs 
control diet same genotype, and ╪╪p<0.01 vs Cre− same diet; n=3–9); (inset) Fgf23 mRNA 
was significantly reduced in Fgf23Δ/f/Col2.3-cre+ mice versus Cre− controls (*p<0.05); (B) 
Fgf23Δ/f/Dmp1-cre+ mice had lower serum intact FGF23 at 8 weeks of age versus Fgf23Δ/f/
Dmp1-cre− while receiving control diet; (inset) femur Fgf23 mRNA was not statistically 
different between Cre+ or Cre− mice. Following high phosphate diet, the rise of serum intact 
FGF23 was blunted in Fgf23Δ/f/Dmp1-cre+ mice (**p<0.01 vs control diet same 
genotype; ╪╪p<0.01 vs Cre− same diet; n=8–12); (C) Serum phosphate was elevated in the 
mice receiving HighP diet, and was significantly higher in Fgf23Δ/f/Col2.3-cre+ versus all 
other groups; Fgf23Δ/f/Dmp1-cre+ mice receiving HighP diet had a trend towards elevated 
serum phosphate and was significantly different from Fgf23Δ/f/Dmp1-cre− mice receiving 
the HighP diet (*p<0.05 and **p<0.01 vs control diet same genotype, ╪p<0.05 
and ╪╪p<0.01 vs Cre- same diet; n=3–12); (D) Serum calcium was not different across 
genotypes or diets; (E) Alkaline phosphatase was reduced in the Fgf23Δ/f/Col2.3-cre+ mice 
receiving HighP diet (*p<0.05 vs control diet same genotype; ╪p<0.05 vs Cre− same diet); 
(F) Serum intact PTH was elevated in Fgf23Δ/f/Col2.3-cre− mice receiving the HighP diet, 
whereas no change was observed for the Fgf23Δ/f/Col2.3-cre+ mice. Only the Fgf23Δ/f/
Dmp1-cre− mice receiving HighP diet had a significant increase in serum PTH (*p<0.05 vs 
control diet same genotype).
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Figure 3. Crossing conditionally-targeted Fgf23 alleles onto the Hyp genetic background
(A) Gross phenotyping showed that the Hyp/Fgf23Δ/f/Col2.3-cre+ were similar to Fgf23Δ/+/
Col2.3-cre+ (phenotypically normal mice) with normal body size and tail length (arrow) 
versus Hyp mice; (B) quantification confirmed Hyp/Fgf23Δ/f/Col2.3-cre+ femur and tail 
lengths were normalized versus Hyp and not different from Fgf23Δ/+/Col2.3-cre+ mice 
(n=3–7 males; **p<0.01 Hyp vs. Fgf23Δ/+/Col2.3-cre+ and Hyp/Fgf23Δ/f/Col2.3-cre+); (C) 
Hyp/Fgf23Δ/f/Col2.3-cre+ mice had significantly reduced basal intact serum FGF23 versus 
Fgf23Δ/+/Col2.3-cre+ and Hyp from weaning to 8 weeks of age (**p<0.01 vs Fgf23Δ/+/
Col2.3-cre+; ╪p<0.05,╪╪p<0.01 vs Hyp/Fgf23Δ/f/Col2.3-cre+; n=5–9); (D) Serum 
phosphate in Hyp/Fgf23Δ/f/Col2.3-cre+ mice was corrected compared to the 
hypophosphatemia in Hyp and not different from Fgf23Δ/+/Col2.3-cre+ mice. Additionally, 
serum PTH was highly elevated in Hyp compared to Fgf23Δ/+/Col2.3-cre+ mice. These 
levels were corrected in the Hyp/Fgf23Δ/f/Col2.3-cre+ mice (*p<0.05, **p<0.01 vs Fgf23Δ/+/
Col2.3-cre+, ╪╪p<0.01 vs Hyp; n=7–9).
Clinkenbeard et al. Page 20
J Bone Miner Res. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Skeletal μCT and histomorphometry of Hyp/Fgf23Δ/f/Col2.3-cre+ mice
(A) As assessed by μCT, compared to Fgf23Δ/+/Col2.3-cre+ mice the metaphyses of Hyp/
Fgf23Δ/f/Col2.3-cre+ lacked marrow space or trabeculae definition due to the abundant bone. 
Hyp mice had lack of trabecular bone and misshapen femoral head. (B) Mid-diaphysis 
images showed reduced porosity and higher bone area relative to total area in Hyp/Fgf23Δ/f/
Col2.3-cre+ versus Hyp; (C) Von Kossa staining of femora qualitatively revealed that Hyp/
Fgf23Δ/f/Col2.3-cre+ mice had resolved the Hyp widened growth plate, distended bone, and 
osteomalacia characteristic of this model; and (D) Histomorphometry demonstrated Hyp/
Fgf23Δ/f/Col2.3-cre+ bone had dynamic bone formation rates similar to Fgf23Δ/+/Col2.3-
cre+ as determined by dual fluorescence labeling whereas Hyp mice had virtually no label 
uptake (upper panels). Enlarged regions of label are boxed and shown beneath their 
respective genotypes (lower panels).
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Table 1
μCT and histomorphometric analyses.
Fgf23Δ/+/Col2.3-cre+ Hyp/Fgf23Δ/f/Col2.3-cre+ Hyp
μCT
Cancellous BV/TV, % 16.2 ± 1.3*** 76.6 ± 8.4*** ╪╪╪ 2.8 ± 0.9
Cortical BA/TA, % 43 ± 1** 40 ± 1** 27 ± 1
Cortical porosity, % 0.06 ± 0.02* 0.48 ± 0.2* 11 ± 5
Cortical thickness, mm 0.16 ± 0.01** 0.15 ± 0.01** 0.08 ± 0.01
Dynamic Histomorphometry
Periosteal MS/BS, % 66 ± 6** 82 ± 6** 18 ± 7
Periosteal MAR, um/day 2.7 ± 0.2** 3.5± 0.4** 0.5 ± 0.5
Periosetal BFR/BS, um3/um2/year 667 ± 83** 1035 ± 106** ╪ 76 ± 76
Endocortical MS/BS, % 60 ± 7** 74 ± 5** 15 ± 6
Endocortical MAR, um/day 2.1 ± 0.2** 2.4 ± 0.1** ND
Endocortical BFR/BS, um3/um2/year 409 ± 97** 538 ± 70** ND
Data presented as mean and standard error (*p<0.05 **p<0.01 and ***p<0.001 vs Hyp, ╪p<0.05 ╪╪p<0.01 and ╪╪╪p<0.001 vs Fgf23Δ/+/
Col2.3-cre+). BV, bone volume; TV, total volume; BA, bone area; TA, total area; MS/BS, mineralizing surface per bone surface; MAR, mineral 
apposition rate; BFR/BS, bone formation rate per bone surface. ‘ND’ is not detectable with reference to the lack of sufficient label uptake within 
the specimens; these were designated as ‘0’ for statistical purposes.
J Bone Miner Res. Author manuscript; available in PMC 2017 June 01.
